Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31173097 | 1.00 | IRAK4 (0.43) | IRAK4ALDH1A1ACHENISCHADRA2A | |
| SCHEMBL1465246 | 0.79 | IRAK4 (0.47) | IRAK4ALDH1A1ACHENISCHADRA2A | |
| SCHEMBL18297671 | 0.79 | DRD1 (0.39) | ALDH1A1KDM4EPOLBKMT2ASLC6A2 | |
| SCHEMBL31543913 | 0.79 | DRD1 (0.39) | ALDH1A1KDM4EPOLBKMT2ASLC6A2 | |
| SCHEMBL1871847 | 0.79 | GAA (0.50) | IRAK4ALDH1A1ACHEADRA2AADRA2B | |
| SCHEMBL29530994 | 0.79 | GAA (0.50) | IRAK4ALDH1A1ACHEADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL13857740 | 0.78 | GAA (0.49) | IRAK4ALDH1A1ACHEADRA2AADRA2B | |
| SCHEMBL28867025 | 0.77 | KCNH2 (0.36) | IRAK4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL7944121 | 0.77 | MAOB (0.31) | ALDH1A1 | |
| SCHEMBL3256317 | 0.77 | MAOB (0.34) | ADRA2AADRA2BADRA2CCYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531823-B | Ruthenium-or osmium-based complex catalysts | 阿朗新科德国有限责任公司 | 2020-11-17 | — | — | CN | claimed |
| US-10441948-B2 | Ruthenium-or osmium-based complex catalysts | ARLANXEO DEUTSCHLAND GMBH (DE) | 2019-10-15 | — | — | US | claimed |
| EP-3283496-B1 | RUTHENIUM- OR OSMIUM-BASED COMPLEX CATALYSTS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2019-06-19 | — | — | EP | claimed |
| US-20180290134-A1 | RUTHENIUM-OR OSMIUM-BASED COMPLEX CATALYSTS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2018-10-11 | — | — | US | claimed |
| EP-3283496-A1 | RUTHENIUM- OR OSMIUM-BASED COMPLEX CATALYSTS | ARLANXEO Deutschland GmbH (DE) | 2018-02-21 | — | — | EP | claimed |
| WO-2016166097-A1 | RUTHENIUM- OR OSMIUM-BASED COMPLEX CATALYSTS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2016-10-20 | — | — | WO | claimed |
| EP-3081572-A1 | RUTHENIUM-OR OSMIUM-BASED COMPLEX CATALYSTS | ARLANXEO Deutschland GmbH (DE) | 2016-10-19 | — | — | EP | claimed |
| US-8110636-B1 | Multi-block sulfonated poly(phenylene) copolymer proton exchange membranes | SANDIA CORPORATION (US) | 2012-02-07 | — | — | US | claimed |
| CN-114907297-B | Method for preparing benzodihydrofuran derivative by tandem connection of visible light catalytic 2-alkynyl aryl ether and sulfonyl chloride | 湖南警察学院 | 2024-09-24 | — | — | CN | disclosed |
| CN-114907297-A | Method for preparing benzodihydrofuran derivative by visible light catalysis of 2-alkynyl aryl ether and sulfonyl chloride in series | 湖南警察学院 | 2022-08-16 | — | — | CN | disclosed |
| CN-107531823-B | Ruthenium-or osmium-based complex catalysts | 阿朗新科德国有限责任公司 | 2020-11-17 | — | — | CN | disclosed |
| US-10441948-B2 | Ruthenium-or osmium-based complex catalysts | ARLANXEO DEUTSCHLAND GMBH (DE) | 2019-10-15 | — | — | US | disclosed |
| EP-3283496-B1 | RUTHENIUM- OR OSMIUM-BASED COMPLEX CATALYSTS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2019-06-19 | — | — | EP | disclosed |
| US-20180290134-A1 | RUTHENIUM-OR OSMIUM-BASED COMPLEX CATALYSTS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2018-10-11 | — | — | US | disclosed |
| EP-3283496-A1 | RUTHENIUM- OR OSMIUM-BASED COMPLEX CATALYSTS | ARLANXEO Deutschland GmbH (DE) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016166097-A1 | RUTHENIUM- OR OSMIUM-BASED COMPLEX CATALYSTS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016166097-A1 | RUTHENIUM- OR OSMIUM-BASED COMPLEX CATALYSTS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2016-10-20 | — | — | WO | disclosed |
| EP-3081572-A1 | RUTHENIUM-OR OSMIUM-BASED COMPLEX CATALYSTS | ARLANXEO Deutschland GmbH (DE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3081572-A1 | RUTHENIUM-OR OSMIUM-BASED COMPLEX CATALYSTS | ARLANXEO Deutschland GmbH (DE) | 2016-10-19 | — | — | EP | disclosed |
| US-8110636-B1 | Multi-block sulfonated poly(phenylene) copolymer proton exchange membranes | SANDIA CORPORATION (US) | 2012-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10441948-B2 | Ruthenium-or osmium-based complex catalysts | OSTC, OSBP, OSBPL3 | IRAK4 4064/4885ALDH1A1 1283/4885ACHE 1855/4885 |
| US-20180290134-A1 | RUTHENIUM-OR OSMIUM-BASED COMPLEX CATALYSTS | OSTC, OSBP, OSBPL3 | IRAK4 4064/4885ALDH1A1 1283/4885ACHE 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.